N/A
N=41
Miromatrix Biological Mesh for Hiatal Hernia Repair
Hiatal Hernia
Bottom Line
View on ClinicalTrials.gov: NCT02436681 ↗Enrolled (actual)
41
Serious AEs
4.9%
Results posted
Sep 2019
Primary outcome: Primary: Number of Subjects With a Hernia Recurrence Requiring Reoperation — 0 Participants
Study Design & Population
- Study type
- Interventional
- Phase
- N/A
- Interventions
- MIROMESH (Device)
- Age
- Adult, Older Adult · 18+ yrs
- Sex
- All
- Sponsor
- Miromatrix Medical Inc.
- Primary completion
- Jul 2018
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Number of Subjects With a Hernia Recurrence Requiring Reoperation |
— | — |
Summary
Miromatrix Medical has developed MIROMESH® - a new, noncrosslinked, acellular mesh derived from the highly vascularized porcine liver. MIROMESH received FDA 510(k) clearance with an indication for reinforcement of soft tissue on March 31, 2014 under K134033. This study will serve to provide clinicians with high-quality clinical data in order to provide them with a higher degree of confidence when selecting MIROMESH for hiatal hernia repair.
Eligibility Criteria
Inclusion Criteria
- between 18 and 80 years old on the day of study enrollment
- able and willing to sign the consent form and comply with all study visits and procedures
- able to undergo elective laparoscopic hiatal hernia repair
- free of cognitive or speech impairment
- documented, symptomatic type II or III hernia ≥5cm in the axial/vertical dimension
- commit to non-smoking for at least 4 weeks prior to procedure
Exclusion Criteria
- previous operation of the esophagus or stomach
- sensitivity to porcine material
- pregnant or plan to be pregnant within next 2 years
- immunocompromised or at risk of immunosuppression (i.e. be HIV positive, be experiencing organ rejection, be a recent or anticipated chemotherapy recipient) as determined by the Investigator
- require emergent operation for acute gastric volvulus or strangulation
- American Society of Anesthesiology (ASA) class 4 or greater
- BMI ≥40
- life expectancy of less than 2 years at the time of enrollment
- associated gastrointestinal disease that requires extensive medical or surgical intervention that might interfere with the quality of life assessment (e.g. Crohn's disease)
- any condition in the opinion of the Investigator that would preclude the use of the study device, or preclude the subject from completing the follow-up requirements
Data sourced from ClinicalTrials.gov (NCT02436681). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.